Medpace Holdings Inc. (MEDP) saw its stock price plummet 5.04% during Wednesday's intraday trading session. The significant drop came as investors reacted to a wave of negative sentiment from Wall Street analysts.

Multiple financial institutions, including BMO, Truist Securities, Barclays, Deutsche Bank, and Mizuho, simultaneously lowered their price targets for the clinical research organization. The reductions were substantial, with Deutsche Bank cutting its target from $600 to $480 and BMO lowering its target from $600 to $460.

While several firms maintained their Hold or equivalent ratings on the stock, the collective downward revisions in price targets created selling pressure. Analyst actions typically influence investor perception of a company's future earnings potential and valuation, leading to the observed market reaction.